Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 13, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,000 | $15.00 | 30,687 | |
| Jul 13, 2015 | SVP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 3,000 | $15.00 | 27,687 | |
| Jul 13, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,000 | -- | 24,000 | |
| Jun 22, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,000 | -- | 27,000 | |
| Sep 29, 2014 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,000 | -- | 73,500 | |
| Sep 08, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 3,000 | $14.83 | 54,116 | |
| Aug 04, 2008 | Director, President & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 3,000 | $15.22 | 20,200 | |
| Mar 05, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 3,000 | $9.64 | 846,018 | |
| Mar 05, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 3,000 | $9.64 | 846,018 | |
| Feb 13, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 3,000 | $10.50 | 629,667 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.